Bing Huang
14 Papers
32 Citations
Bing Huang is an academic researcher. The author has contributed to research in topics: Neuraminidase & Oseltamivir. The author has an hindex of 8, co-authored 14 publications.
Chat about Author
Papers
Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
Yuanchao Xie,Dongqing Xu,Bing Huang,Xiuli Ma,Wenbao Qi,Fangyuan Shi,Xinyong Liu,Yingjie Zhang,Wenfang Xu +8 more
TL;DR: The present work is a significant breakthrough in the discovery of potent group-1-specific neuraminidase inhibitors, which may be further investigated for the treatment of infection by the H5N1 virus.
69
Caffeic acid derivatives: A new type of influenza neuraminidase inhibitors
TL;DR: Caffeic acid which contained two phenolic hydroxyl groups as the basic fragment was taken to build a small compound library to discover more potent NA inhibitors from caffeic acid derivatives to cope with influenza virus.
55
Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant
Jian Zhang,Vasanthanathan Poongavanam,Dongwei Kang,Chiara Bertagnin,Huamei Lu,Xiujie Kong,Han Ju,Xueyi Lu,Ping Gao,Ye Tian,Haiyong Jia,Samuel Desta,Xiao Ding,Lin Sun,Zengjun Fang,Boshi Huang,Xuewu Liang,Ruifang Jia,Xiuli Ma,Wenfang Xu,Natarajan Arul Murugan,Arianna Loregian,Bing Huang,Peng Zhan,Xinyong Liu +24 more
TL;DR: The successful exploitation of the 150-cavity of NAs represents an important breakthrough in the development of more potent anti-influenza agents and Computational modeling and molecular dynamics studies provided insights into the role of R group of 15b in improving potency toward group-1 and -2 NAs.
54
Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
Jian Zhang,Natarajan Arul Murugan,Ye Tian,Chiara Bertagnin,Zengjun Fang,Dongwei Kang,Xiujie Kong,Haiyong Jia,Zhuosen Sun,Ruifang Jia,Ping Gao,Vasanthanathan Poongavanam,Arianna Loregian,Wenfang Xu,Xiuli Ma,Xiao Ding,Bing Huang,Peng Zhan,Xinyong Liu +18 more
TL;DR: Five subseries of oseltamivir derivatives were designed and synthesized to improve their activity toward drug-resistant viral strains by further exploiting the 150-cavity in the neuraminidases (NAs) to make 21h a promising drug candidate for the treatment of influenza virus infection.
37
Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity.
TL;DR: A novel series of 1,2,3-triazole oseltamivir derivatives, which could simultaneously occupy the classical NA catalytic site and the newly reported 430-cavity, were designed, synthesized, and evaluated for their anti-influenza activities.
35